#None #Viva Biotech #AI Drug Development #CRO Growth

Viva Biotech's 2024 Annual Report Highlights

On March 27, 2025, Viva Biotech Holdings, known for its leadership in the biopharmaceutical industry, released its annual results for the year ending December 31, 2024. The report reveals significant financial recovery, aided by innovative advancements in artificial intelligence (AI) that are reshaping drug research and development (R&D).

Financial Recovery and Growth

Viva Biotech has reported impressive figures for 2024, with revenue soaring to RMB 1,986.7 million. The gross profit reached RMB 687.4 million, leading to a net profit of RMB 222.0 million, marking a stark contrast from the net loss of RMB 99.8 million in the previous year. The company attributed this remarkable turnaround to the repayment of convertible bonds, resulting in the elimination of financial adjustments and an operational efficiency improvement that propelled operating profit margins. Moreover, the adjusted non-IFRS net profit grew by nearly 50.6% year-on-year, highlighting sustained growth in its Contract Research Organization (CRO) business segment.

Advances in CRO Business

Although the revenue for the CRO sector saw a slight decline of approximately 4% compared to the previous year, the second half of 2024 showcased a turnaround. The company observed a recovery in global biopharmaceutical investments, reflecting positively in CRO revenue growth. With a total of 1,568 CRO customers, including top-tier pharmaceutical companies globally, the potential for revenue increase in 2025 looks promising.

In terms of research output, by the end of 2024, Viva Biotech delivered over 82,716 unique protein structures to clients and identified 2,098 independent drug targets, maintaining a leadership position in protein structure analysis. The significant engagement with AI in enhancing productivity and project efficiency further positions the company for a robust future.

A Leading Role for AI in Drug Discovery

Recognizing AI's transformative potential, Viva Biotech has integrated this technology comprehensively throughout its drug discovery processes. By employing AI-driven methodologies, the firm engages in a broader array of projects while simultaneously improving the success rate of drug candidates. In 2024 alone, the company participated in 157 AI-driven drug discovery projects, generating over USD 10 million in revenues from AI-enabled initiatives.

Strengthening the CMC Business

Additionally, the firm acquired Zhejiang Langhua Pharmaceutical Co., Ltd., securing a robust position in commercial drug production. The operational optimization here reflects ongoing efforts to expand the company's capacity, with projections for commercial launches in the forthcoming years. With a commitment to quality management and adherence to international standards, the CDMO services developed by Langhua represent a strategic foundation for driving future revenue growth.

Investments and Exits

Viva Biotech's investment strategy has also yielded positive returns. The company continues to realize profits from its incubation portfolio, achieving partial exits and generating approximately RMB 162.5 million. Engaging with numerous biotech startups across North America and Asia, this approach will likely support ongoing revenue streams, especially as successful companies advance to financing rounds.

Conclusion: A Vision for the Future

Dr. Mao Chen Cheney, Chairman and CEO of Viva Biotech, emphasized the potential of the company's unique capabilities in structure-based drug discovery (SBDD) and the integration of chemical and biological services. With continuous investment in technology, operational capacity, and strategic partnerships, Viva Biotech is well-positioned to bolster its role as a global player in the biopharmaceutical arena, driving innovation and enhancing drug creation efficiency while solidifying its market presence in the years to come.